NCT00317902View on ClinicalTrials.gov

An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)

PHASE4CompletedINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

May 31, 2004

Conditions
AnemiaHIV Infections
Interventions
DRUG

Epoetin alfa

All Listed Sponsors
lead

Ortho Biotech Products, L.P.

INDUSTRY

NCT00317902 - An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II) | Biotech Hunter | Biotech Hunter